Patents by Inventor Andranik Andrew Aprikyan

Andranik Andrew Aprikyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230116019
    Abstract: The disclosure provides methods and compositions for delivering RNA constructs to cells for functional expression and/or activity. In some aspects, the disclosure provides a composition comprising a multi-functionalized nanoparticle. The multi-functionalized nanoparticles comprise a core functionalized with at least one RNA molecule, at least one cell penetrating peptide (CPP), and at least one positively charged moiety, each of which is independently attached to the core, optionally with linker moieties. In some embodiments, the RNA molecule is an uncapped mRNA molecule with the 5? end attached to a linker moiety that is attached to the core. The multi-functionalized nanoparticle is substantially neutral, negatively or positively charged.
    Type: Application
    Filed: January 8, 2021
    Publication date: April 13, 2023
    Applicant: Stemgenics, Inc.
    Inventor: Andranik Andrew Aprikyan
  • Publication number: 20210154323
    Abstract: Provided are functionalized nanoparticles for penetrating through a mammalian cell membrane and delivering intracellularly one or more biologically active molecules comprising a nanoparticle core, one or more cell membrane-penetrating molecule(s), and one or more biologically active molecule(s) for introducing or affecting one or more cellular function(s). functionalized nanoparticles. Also provided are methods for making functionalized nanoparticles and methods for using functionalized nanoparticles, including methods for treating diseases and disorders, inducing the reprograming of cells, and for gene editing.
    Type: Application
    Filed: June 3, 2017
    Publication date: May 27, 2021
    Applicant: STEMGENICS, INC.
    Inventors: Andranik Andrew Aprikyan, Killian Dill
  • Publication number: 20190233820
    Abstract: This disclosure relates to compositions and methods for editing or altering target nucleotide sequences based on nanoparticle delivery vehicles. The compositions and methods can be applied to influence the functional expression of target gene products encoded by DNA and/or RNA. In some embodiments, the altered gene sequences are useful to normalize and regulate the function of target cells.
    Type: Application
    Filed: October 11, 2017
    Publication date: August 1, 2019
    Applicant: STEMGENICS, INC.
    Inventor: Andranik Andrew Aprikyan
  • Publication number: 20190224335
    Abstract: This disclosure relates to compositions and methods for reprogramming an initial cell (e.g., somatic cell) to generate specialized cell types of interest, such as cardiac, hepatic, blood, neuronal and other cells from human somatic cells. In some embodiments, initial (e.g., somatic) cell is a human cell thus producing human induced cell types of interest. In some embodiments, the compositions and methods incorporate nanoparticles functionalized with biologically active molecules (RNAs, proteins, peptides and other small molecules). These newly generated (i.e., “induced”) specialized cells are useful to improve organ function and/or tissue regeneration (heart, liver, etc.) and to screen drugs for functional activity.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 25, 2019
    Applicant: STEMGENICS, INC.
    Inventor: Andranik Andrew Aprikyan
  • Publication number: 20180223260
    Abstract: Provided are functionalized nanoparticles for penetrating through a mammalian cell membrane and delivering intracellularly one or more biologically active molecules comprising a nanoparticle core, one or more cell membrane-penetrating molecule(s), and one or more biologically active molecule(s) for introducing or affecting one or more cellular function(s). functionalized nanoparticles. Also provided are methods for making functionalized nanoparticles and methods for using functionalized nanoparticles, including methods for treating diseases and disorders, inducing the reprogramming of cells, and for gene editing.
    Type: Application
    Filed: June 3, 2017
    Publication date: August 9, 2018
    Applicant: STEMGENICS, INC.
    Inventors: Andranik Andrew Aprikyan, Kilian Dill
  • Patent number: 9675708
    Abstract: Functionalized biocompatible nanoparticles capable of penetrating through a mammalian cell membrane and delivering intracellularly a plurality of bioactive molecules for modulating a cellular function are disclosed herein The functionalized biocompatible nanoparticles comprise: a central nanoparticle ranging in size from about 5 to about 50 nm and having a polymer coating thereon, a plurality of functional groups covalently attached to the polymer coating, wherein the plurality of bioactive molecules are attached to the plurality of the functional groups, and wherein the plurality of bioactive molecules include at least a peptide and a protein, and wherein the peptide is capable of penetrating through the mammalian cell membrane and entering into the cell, and wherein the protein is capable of providing a new functionality within the cell. The protein may be a transcription factor selected from the group consisting of Oct4, Sox2, Nanog, Lin28, cMyc, and Klf4.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 13, 2017
    Assignee: Stemgenics, Inc.
    Inventors: Andranik Andrew Aprikyan, Kilian Dill
  • Publication number: 20140342004
    Abstract: Functionalized biocompatible nanoparticles capable of penetrating through a mammalian cell membrane and delivering intracellularly a plurality of bioactive molecules for modulating a cellular function are disclosed herein The functionalized biocompatible nanoparticles comprise: a central nanoparticle ranging in size from about 5 to about 50 nm and having a polymer coating thereon, a plurality of functional groups covalently attached to the polymer coating, wherein the plurality of bioactive molecules are attached to the plurality of the functional groups, and wherein the plurality of bioactive molecules include at least a peptide and a protein, and wherein the peptide is capable of penetrating through the mammalian cell membrane and entering into the cell, and wherein the protein is capable of providing a new functionality within the cell. The protein may be a transcription factor selected from the group consisting of Oct4, Sox2, Nanog, Lin28, cMyc, and Klf4.
    Type: Application
    Filed: October 22, 2012
    Publication date: November 20, 2014
    Inventors: Andranik Andrew Aprikyan, Kilian Dill
  • Patent number: 8283344
    Abstract: The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 9, 2012
    Assignees: Merck & Co., Inc., University of Washington
    Inventors: David C. Dale, Paul E. Finke, Richard A. Mumford, Andranik Andrew Aprikyan
  • Publication number: 20110059960
    Abstract: The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 5, 2008
    Publication date: March 10, 2011
    Inventors: David C. Dale, Paul E. Finke, Richard A. Munford, Andranik Andrew Aprikyan